메뉴 건너뛰기
New England Journal of Medicine
Volumn 377, Issue 5, 2017, Pages 496-497
Tofacitinib as induction and maintenance therapy for ulcerative colitis
Author keywords

[No Author keywords available]
Indexed keywords

AZATHIOPRINE; GLUCOCORTICOID; INTERLEUKIN 10; INTERLEUKIN 22; JANUS KINASE 1; JANUS KINASE 3; MERCAPTOPURINE; MESALAZINE; TOFACITINIB;
EID: 85026784186     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1707500     Document Type: Letter
Times cited : (110)
References (5)
  • 1
    • 85026745558 scopus 로고    scopus 로고
    • Tofacitinib for induction therapy in patients with active ulcerative colitis in two phase 3 clinical trials: Results by local and central endoscopic assessments
    • Feagan BG, Vermeire S, Sandborn WJ, et al. Tofacitinib for induction therapy in patients with active ulcerative colitis in two phase 3 clinical trials: results by local and central endoscopic assessments. Am J Gastroenterol 2016;111:Suppl:S1:S319.
    • (2016) Am J Gastroenterol , vol.111 , Issue.S1 , pp. S319
    • Feagan, B.G.1    Vermeire, S.2    Sandborn, W.J.3
  • 2
    • 84882769357 scopus 로고    scopus 로고
    • Vedolizumab as induction and maintenance therapy for ulcerative colitis
    • Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
    • (2013) N Engl J Med , vol.369 , pp. 699-710
    • Feagan, B.G.1    Rutgeerts, P.2    Sands, B.E.3
  • 3
    • 84856163835 scopus 로고    scopus 로고
    • Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis
    • e1-3
    • Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142(2): 257-65.e1-3.
    • (2012) Gastroenterology , vol.142 , Issue.2 , pp. 257-265
    • Sandborn, W.J.1    Van Assche, G.2    Reinisch, W.3
  • 4
    • 84880076939 scopus 로고    scopus 로고
    • Why interleukin-10 supplementation does not work in Crohn’s disease patients
    • Marlow GJ, van Gent D, Ferguson LR. Why interleukin-10 supplementation does not work in Crohn’s disease patients. World J Gastroenterol 2013;19:3931-41.
    • (2013) World J Gastroenterol , vol.19 , pp. 3931-3941
    • Marlow, G.J.1    Van Gent, D.2    Ferguson, L.R.3
  • 5
    • 84891702406 scopus 로고    scopus 로고
    • Therapeutic opportunities of the IL-22-IL-22R1 system
    • Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 2014;13:21-38.
    • (2014) Nat Rev Drug Discov , vol.13 , pp. 21-38
    • Sabat, R.1    Ouyang, W.2    Wolk, K.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.